Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Interferon as long-term treatment for hepatitis C not effective

Interferon as long-term treatment for hepatitis C not effective

Low-dose peginterferon used for hepatitis C doesn't work

Low-dose peginterferon used for hepatitis C doesn't work

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Researchers develop new strategy for broad spectrum anti-viral drugs

Researchers develop new strategy for broad spectrum anti-viral drugs

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

GSK to acquire Genelabs Technologies

GSK to acquire Genelabs Technologies

Anti-itching drug clemizole shows promise against hepatitis C

Anti-itching drug clemizole shows promise against hepatitis C

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

Hepatitis C therapy peginterferon alfa-2b shows promise

Hepatitis C therapy peginterferon alfa-2b shows promise

Risk factors for severe RSV infection in immunocompromised children

Risk factors for severe RSV infection in immunocompromised children

Shorter HCV treatment shows notable success

Shorter HCV treatment shows notable success

Optimal therapy for U.S. hepatitis C patients

Optimal therapy for U.S. hepatitis C patients

Hepatitis C treatment reduces the virus but serious liver problems may progress

Hepatitis C treatment reduces the virus but serious liver problems may progress

New mechanism discovered that mammalian cells employ to fight infections of the Hepatitis C virus

New mechanism discovered that mammalian cells employ to fight infections of the Hepatitis C virus

Can liver cirrhosis be partially cured?

Can liver cirrhosis be partially cured?

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Case report on a shining significance in living donor transplantation

Case report on a shining significance in living donor transplantation

FDA fast tracks ViroPharma's treatment of hepatitis C

FDA fast tracks ViroPharma's treatment of hepatitis C

When HIV and liver disease co-exist

When HIV and liver disease co-exist

A cure for Hepatitis C using existing treatments

A cure for Hepatitis C using existing treatments